HK Stock Market Move | RIMBACO (01953) surged over 14% in late trading and will officially rename itself to Cyvax International next week. The company's net profit in the first half of the year increased nearly fourfold year-on-year.
RIMBACO (01953) surged over 14% in late trading. As of the time of writing, it rose 12.44%, trading at HKD 1.265, with a transaction volume of HKD 9.4466 million.
RIMBACO (01953) surged over 14% in late trading, and as of the time of writing, it is up 12.44%, priced at HKD 1.265, with a trading volume of HKD 9.4466 million.
In news, on September 2, RIMBACO announced that following the approval of a special resolution at a special general meeting by the shareholders to change the company's name, the company's English name has been changed from "Rimbaco Group Global Limited" to "SFQ Global Limited," based on the certificate of the change of company name issued by the Registrar of Companies of the Cayman Islands on August 6, 2026. The Chinese name "" has been adopted and registered as the company's dual foreign name, both effective from August 6, 2026.
Following the name change, the English stock abbreviation for the company's shares traded on the Stock Exchange will change from "RIMBACO" to "SFQ GLOBAL," with "" adopted as the Chinese stock abbreviation, effective from 9:00 a.m. on September 7, 2026. Previously, RIMBACO disclosed its performance for the first half of 2026, reporting revenue of 183 million MYR, a year-on-year increase of 50.6%; net profit of 15.753 million MYR, a year-on-year increase of 398%. The increase in revenue during this period was primarily due to the completion of a fast-track factory project in the first half of the fiscal year 2026.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





